Dbv Technologies S.A. (DBVT) Stock Price & Analysis
Dbv Technologies S.A. (DBVT) fell 1.66% to USD 13.63 as of July 26, 2026 at 19:00 UTC, according to Nexqual real-time market data.
DBVT last closed at USD 13.86; the session ranged USD 13.41–13.79 on volume of 190,911 shares. Market capitalization is $806.66M, with a 52-week range of USD 8.51–26.19 (NCM). Source: Nexqual, July 26, 2026 at 19:00 UTC.
Key Statistics (as of July 26, 2026 at 19:00 UTC)
| Price | USD 13.63 |
|---|---|
| Change | ▼ 1.66% (down) |
| Previous Close | USD 13.86 |
| Open | USD 13.74 |
| Day Range | USD 13.41 – 13.79 |
| 52-Week Range | USD 8.51 – 26.19 |
| Volume | 190,911 shares |
| Market Cap | $806.66M |
| Exchange | NCM |
Technical Analysis (DBVT)
Nexqual's technical model rates DBVT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 19:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.55 (neutral) |
| vs SMA50 | Below (USD 16.73) |
| MACD | -0.82 (negative) |
Analyst Ratings (DBVT)
Wall Street analysts rate DBVT "Buy" based on 6 analysts, with a mean price target of USD 40.57 (range USD 5.78–54.69), per Nexqual as of July 26, 2026 at 19:00 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 40.57 |
| High Target | USD 54.69 |
| Low Target | USD 5.78 |
| Buy / Hold / Sell | 5 / 0 / 1 |
Earnings (DBVT)
| Next Earnings Date | 2026-07-16 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $580,830 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est -0.09 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.2 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.29 ▲ beat |
Source: Nexqual, July 26, 2026 at 19:00 UTC.
Financials & Fundamentals (DBVT)
| Total Revenue | $5.04M |
|---|---|
| Revenue Growth (YoY) | -53.30% |
| Gross Margin | +100.00% |
| Operating Margin | -7228.57% |
| Profit Margin | +0.00% |
| ROE | -142.68% |
| Debt / Equity | 4.8 |
| Current Ratio | 3.72 |
| Total Cash | $174.90M |
| Total Debt | $7.70M |
| Free Cash Flow | $-104.85M |
Source: Nexqual, July 26, 2026 at 19:00 UTC.
Financial Health Score (DBVT)
Nexqual rates Dbv Technologies S.A.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 19:00 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $175M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$105M, burning cash |
| Efficiency | Critical — ROE -143%, ROA -60.6% |
Ownership (DBVT)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +37.21% |
| Shares Outstanding | 59.18M |
| Float | 35.25M |
| Short % of Float | +2.49% |
Source: Nexqual, July 26, 2026 at 19:00 UTC.
Leadership (DBVT)
Dbv Technologies S.A. is led by Daniel Tassé (age 65), CEO & Director, per Nexqual as of July 26, 2026 at 19:00 UTC.
| CEO & Director | Daniel Tassé (age 65) |
|---|---|
| Chief Financial Officer | Virginie Simone Jeanine Verrechia Boucinha (age 56) |
Major Backers & Investors (DBVT)
Notable institutional backers of Dbv Technologies S.A. include MPM Bioimpact LLC, Artisan Partners Limited Partnership, Vivo Capital, LLC, according to Nexqual as of July 26, 2026 at 19:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 8.8% |
| Artisan Partners Limited Partnership | 6.05% |
| Vivo Capital, LLC | 4.51% |
| Siren, L.L.C. | 3.14% |
| Baker Bros. Advisors, LP | 2.47% |
| Adar1 Capital Management, LLC | 1.71% |
| Perceptive Advisors Llc | 1.63% |
| Patient Square Capital LP | 1.17% |
Source: Nexqual, July 26, 2026 at 19:00 UTC.
From Dbv Technologies S.A.'s Latest SEC 10-K Filing (filed 2026-03-26)
Partnerships
- With Sanofi On August 29, 2025, the Company entered into the Supply Agreement with SANOFI, under which SANOFI will manufacture and supply the Viaskin Peanut API for the Company.
- Manufacturing Supply Agreement - PSM "Peanut Source Material " Fareva La Vallée - March 17, 2026 The Company entered into the MS Agreement with FLV, under which the CMO will manufacture and supply PSM, exclusively for DBV Technologies S.A. during the agreement term.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| IFRX | InflaRx N.V. | USD 1.74 | ▼ 3.33% |
| ACRS | Aclaris Therapeutics, Inc. | USD 5.23 | ▼ 6.94% |
| ASMB | Assembly Biosciences, Inc. | USD 25.55 | ▼ 1.88% |
| CLSDQ | Clearside Biomedical, Inc. | USD 0.25 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 19:00 UTC. This page is informational and not investment advice.